Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-01

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Following screening visit and verification of inclusion/exclusion criteria and informed consent, participants will undergo a multiple sleep latency test (MSLT) and polysomnogram (PSG) assessments to confirm eligibility for randomization. Participants will be randomized to two groups: placebo or XW10172 MR. The drug will be taken orally at bedtime for 6 weeks of treatment that will consist of a 2-week dose escalation/titration period and a 4-week stable-dose maintenance period. There will be a 2-week safety period following dosing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease

NCT02473562

Parkinson's Disease

TERMINATED PHASE4

A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

NCT00407212

Parkinson's Disease

COMPLETED PHASE1/PHASE2

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569

Parkinson Disease

COMPLETED PHASE2

A Pilot Study of Oxaloacetate in Subjects With Treated PD

NCT01741701

Parkinson's Disease

COMPLETED PHASE2/PHASE3

A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients

NCT04220762

Parkinson Disease

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Excessive Daytime Somnolence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Valiloxybate

XW10172 Modified Release (MR) Granules for Oral Suspension

Group Type EXPERIMENTAL

Valiloxybate

Intervention Type DRUG

XW10172 MR Granules for Oral Suspension

Placebo

Placebo Granules for Oral Suspension

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo Granules for Oral Suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Valiloxybate

XW10172 MR Granules for Oral Suspension

Intervention Type DRUG

Placebo

Placebo Granules for Oral Suspension

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

XW10172 MR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Parkinson's disease consistent with the UK-PD Society Brain Bank Criteria and PD duration at least 1 year with modified Hoehn and Yahr stage 1-3 in the OFF state.
* Patient reported history of excessive daytime sleepiness (e.g., frequent dozing, nodding, or naps).
* Anti-Parkinson's medications at stable doses for at least 1 month prior to the Baseline Visit and can maintain a fixed, stable dose throughout the study
* Epworth Sleepiness Scale score of \>10 at screening.
* Female participants of childbearing potential must test negative in a serum pregnancy test at Screening and have a negative urine pregnancy test at the Baseline and Visit. Women with childbearing potential must use an acceptable method of contraception during the study and for at least 30 days after completion of dosing.

Exclusion Criteria

* Atypical or secondary parkinsonism
* Significant medical conditions.
* Evidence of moderate or severe sleep disordered breathing.
* Drugs that affect sleep including CNS depressants and stimulants.
* Montreal Cognitive Assessment (MoCA) examine score \<24.
* Hospital Anxiety and Depression Scales (HADS) \>11.
* Have an occupation that requires variable shift work or routine night shifts or travel across two or more-time zones.

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No